Low Anti-SARS-CoV-2 S Antibody Levels Predict Increased Mortality
By LabMedica International staff writers Posted on 20 Oct 2021 |
Image: Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients (Photo courtesy of Instituto de Salud Carlos III)
Anti-SARS-CoV-2 spike (S) antibodies bind to multiple domains in this viral protein. Host antibodies directed at the receptor binding domain (RBD) mediate inhibition of viral attachment to cell surface receptors.
Anti-S antibodies could play a role in reducing viral replication during an ongoing acute infection by interfering with virus entry into a cell. Interestingly, whether levels of host-produced endogenous antibodies against the S protein could influence mortality risk in severe COVID-19 has not been sufficiently studied.
A large team of medical scientists associated with the Instituto de Salud Carlos III (Madrid, Spain) recruited 92 critically ill adult patients with a positive nasopharyngeal swab polymerase chain reaction (PCR) test for SARS-CoV-2 from 16th March to 15th April 2020, during the first pandemic wave from several hospitals. They obtained EDTA plasma in the first 24 hours following admission to the Intensive Care Unit (ICU).
The scientists quantified SARS-CoV-2 RNA in plasma using the Bio-Rad SARS-CoV-2 droplet digital PCR kit (Bio-Rad, Hercules, CA, USA). The team developed a specific immunoassay to quantify anti-SARS-CoV-2 S IgG and IgM antibodies in plasma and evaluated the presence/absence of N antigen of SARS-CoV-2 in plasma using the Panbio COVID-19 Ag Rapid Test Device (Abbott, Chicago, IL, USA).
The investigators reported that the frequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Ten patients (of the total cohort) had no detectable levels in the plasma of anti-SARS-CoV-2 S IgG, and 13 had no detectable levels of anti-SARS-CoV-2 S IgM. Patients who died showed more often absence/lower levels of anti-SARS-CoV-2 S IgM and IgG than those who survived by day 30 following ICU admission. In contrast to that observed for antibodies, non-survivors showed more frequently the presence of antigenaemia along with higher viral RNA loads in plasma. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality. Viral RNA-load in plasma and N-antigenaemia predicted increased mortality.
Jesús F. Bermejo-Martin, MD, PhD, a Clinical Immunologist and a co-senior author of the study, said, “Our findings support that treatment with exogenous antibodies in COVID-19 should be personalized, reserving this therapy for those patients with absent or low endogenous antibodies levels.”
The authors concluded that low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19 and their findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2. The study was published on October 5, 2021 in the Journal of Internal Medicine.
Related Links:
Instituto de Salud Carlos III
Bio-Rad
Abbott
Anti-S antibodies could play a role in reducing viral replication during an ongoing acute infection by interfering with virus entry into a cell. Interestingly, whether levels of host-produced endogenous antibodies against the S protein could influence mortality risk in severe COVID-19 has not been sufficiently studied.
A large team of medical scientists associated with the Instituto de Salud Carlos III (Madrid, Spain) recruited 92 critically ill adult patients with a positive nasopharyngeal swab polymerase chain reaction (PCR) test for SARS-CoV-2 from 16th March to 15th April 2020, during the first pandemic wave from several hospitals. They obtained EDTA plasma in the first 24 hours following admission to the Intensive Care Unit (ICU).
The scientists quantified SARS-CoV-2 RNA in plasma using the Bio-Rad SARS-CoV-2 droplet digital PCR kit (Bio-Rad, Hercules, CA, USA). The team developed a specific immunoassay to quantify anti-SARS-CoV-2 S IgG and IgM antibodies in plasma and evaluated the presence/absence of N antigen of SARS-CoV-2 in plasma using the Panbio COVID-19 Ag Rapid Test Device (Abbott, Chicago, IL, USA).
The investigators reported that the frequency of N-antigenaemia was >2.5-fold higher in absence of antibodies. Ten patients (of the total cohort) had no detectable levels in the plasma of anti-SARS-CoV-2 S IgG, and 13 had no detectable levels of anti-SARS-CoV-2 S IgM. Patients who died showed more often absence/lower levels of anti-SARS-CoV-2 S IgM and IgG than those who survived by day 30 following ICU admission. In contrast to that observed for antibodies, non-survivors showed more frequently the presence of antigenaemia along with higher viral RNA loads in plasma. Antibodies correlated inversely with viral RNA-load in plasma, representing a protective factor against mortality. Viral RNA-load in plasma and N-antigenaemia predicted increased mortality.
Jesús F. Bermejo-Martin, MD, PhD, a Clinical Immunologist and a co-senior author of the study, said, “Our findings support that treatment with exogenous antibodies in COVID-19 should be personalized, reserving this therapy for those patients with absent or low endogenous antibodies levels.”
The authors concluded that low anti-SARS-CoV-2 S antibody levels predict mortality in critical COVID-19 and their findings support that these antibodies contribute to prevent systemic dissemination of SARS-CoV-2. The study was published on October 5, 2021 in the Journal of Internal Medicine.
Related Links:
Instituto de Salud Carlos III
Bio-Rad
Abbott
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms